Department of Medicine, Division of Hematology, Oncology, and Transplantation, University of Minnesota Medical School, Minneapolis, Minn., USA.
Transl Res. 2013 Apr;161(4):355-64. doi: 10.1016/j.trsl.2012.12.010. Epub 2013 Jan 10.
The field of oncolytic virus therapy, the use of live, replicating viruses for the treatment of cancer, has expanded rapidly over the past decade. Preclinical models have clearly demonstrated anticancer activity against a number of different cancer types. Several agents have entered clinical trials and promising results have led to late stage clinical development for some viruses. The early clinical trials have demonstrated that oncolytic viruses by themselves have potential to result in tumor regression. Engineering of viruses to express novel genes have also led to the use of these vectors as a novel form of gene therapy. As a result, interest in oncolytic virus therapy has gained traction. The following review will focus on the first wave of clinical translation of oncolytic virus therapy, what has been learned so far, and potential challenges ahead for advancing the field.
溶瘤病毒治疗领域，即利用活的、复制的病毒来治疗癌症，在过去十年中迅速发展。临床前模型清楚地表明，针对多种不同类型的癌症具有抗癌活性。一些药物已进入临床试验，一些病毒的后期临床试验也取得了有前景的结果。早期临床试验表明，溶瘤病毒本身具有使肿瘤消退的潜力。对病毒进行工程改造以表达新基因，也使得这些载体成为一种新型的基因治疗方法。因此，人们对溶瘤病毒治疗的兴趣日益增加。本综述将重点介绍溶瘤病毒治疗的首次临床转化，迄今为止的经验教训，以及推进该领域的潜在挑战。
